文献速递肝病消化道肿瘤与早癌

雌激素替代治疗降低女性肝细胞癌风险并延长生存时间

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-06-01

该病例对照研究纳入2004年1月1日至2015年5月31日在一家三级医疗中心接受治疗的234例女性肝细胞癌患者和282名健康女性对照,收集环境暴露、初潮与绝经年龄、子宫切除史及避孕药和绝经激素治疗使用情况,采用多因素logistic和Cox回归分析。结果显示曾使用雌激素的女性肝细胞癌调整比值比为0.53(95%CI 0.32-0.88),雌激素使用者肝癌发病年龄更晚、长期使用(超过5年)者风险更低(AOR 0.36,95%CI 0.20-0.63),且雌激素使用降低肝癌死亡风险(HR 0.55,95%CI 0.40-0.77,P=0.01),中位总生存期在雌激素使用者为33.5个月、非使用者为24.1个月(P=0.008)。作者结论认为雌激素绝经激素治疗与肝细胞癌风险降低及总生存时间延长相关,需进一步研究以确定雌激素治疗对女性和肝细胞癌患者的获益及肿瘤雌激素受体表达的影响。

要点

  • 曾使用雌激素的女性肝细胞癌调整比值比为0.53(95%CI 0.32-0.88)。
  • 雌激素使用者肝癌发病年龄更晚(平均64.5±0.9岁 vs 非使用者59.2±1.1岁,P=0.001)。
  • 雌激素使用降低肝癌死亡风险(HR 0.55,95%CI 0.40-0.77,P=0.01)。

核心结论

  • 在这项单中心女性肝细胞癌患者与女性对照的病例对照研究中,雌激素绝经激素治疗的使用与肝细胞癌风险降低及患者总生存时间延长相关。
  • 作者指出需进一步研究以确定雌激素治疗对女性和肝细胞癌患者的获益,以及肿瘤雌激素受体表达的影响。

研究设计与样本

  • 病例对照研究,纳入2004年1月1日至2015年5月31日在一家三级医疗中心接受治疗的234例女性肝细胞癌患者和282名健康女性对照。
  • 收集环境暴露、初潮与绝经年龄、子宫切除史及避孕药和绝经激素治疗使用情况,采用多因素logistic和Cox回归分析。

主要发现

  • 曾使用雌激素的女性肝细胞癌调整比值比为0.53(95%CI 0.32-0.88)。
  • 雌激素使用者肝癌发病平均年龄为64.5±0.9岁,非使用者为59.2±1.1岁(P=0.001)。
  • 长期使用雌激素(超过5年)者肝细胞癌调整比值比为0.36(95%CI 0.20-0.63)。
  • 雌激素使用者肝炎相关肝细胞癌的调整比值比为4.37(95%CI 1.67-11.44),非使用者为17.60(95%CI 3.88-79.83)。
  • 雌激素使用降低肝细胞癌死亡风险(HR 0.55,95%CI 0.40-0.77,P=0.01);中位总生存期在雌激素使用者为33.5个月(95%CI 25.7-41.3个月),非使用者为24.1个月(95%CI 19.02-29.30个月,P=0.008)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出需进一步研究以确定雌激素治疗对女性和肝细胞癌患者的获益,以及肿瘤雌激素受体表达的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Environmental factors have been identified that affect risk of hepatocellular carcinoma (HCC), but little is known about the effects of sex hormones on liver cancer development or outcome. The authors investigated whether menopause hormone therapy (MHT) affects risk, age at onset, or outcome of HCC. METHODS: We performed a case-control study of 234 female patients treated for HCC at a tertiary medical center and with 282 healthy women (controls) from January 1, 2004 through May 31, 2015. We collected detailed information on environmental exposures, ages of menarche and menopause, hysterectomies, and uses of birth control and MHT. We performed multivariable logistic and Cox regression analyses to determine the independent effects of factors associated with women on risk and clinical outcome in HCC. The primary outcomes were effect of MHT on HCC risk, the relationship between MHT with hepatitis virus infection on HCC development, and effect of MHT on age at HCC onset or survival after diagnosis of HCC. RESULTS: The estimated adjusted odds ratio (AOR) for HCC in women who ever used estrogen was 0.53 (95% confidence interval [CI], 0.32-0.88). This association was supported by the older age of HCC onset among estrogen users (mean, 64.5 ± 0.9 years) vs nonusers (mean 59.2 ± 1.1 years; P = .001) and the reduced risk of HCC among long-term users (more than 5 years) (AOR, 0.36; 95% CI, 0.20-0.63). Users of estrogen also had a reduced risk for hepatitis-associated HCC: AOR for users, 4.37 (95% CI, 1.67-11.44) vs AOR for nonusers, 17.60 (95% CI, 3.88-79.83). Estrogen use reduced risk of death from HCC (hazard ratio, 0.55; 95% CI, 0.40-0.77; P = .01). Median overall survival times were 33.5 months for estrogen users (95% CI, 25.7-41.3 months) and 24.1 months for nonusers (95% CI, 19.02-29.30 months; P = .008). CONCLUSION: In a case-control study of women with HCC vs female control subjects at a single center, we associated use of estrogen MHT with reduced risk of HCC and increased overall survival times of patients with HCC. Further studies are needed to determine the benefits of estrogen therapy for women and patients with HCC, and effects of tumor expression of estrogen receptor.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hassan MM, Botrus G, Abdel-Wahab R, et al. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017. PMID: 28579181. doi:10.1016/j.cgh.2017.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。